Edward Fishman: The Collapse of the Oil Empire?
EPISODE SUMMARY Podcast host Alex Gabuev is joined by Edward Fishman, a senior research scholar at the Center on Global Energy Policy at Columbia University,…
Thought Leader: Edward Fishman
Can an inflation cap on drugs be inflationary?
By Scott Gottlieb (original source AEI)
Members of the Senate Finance Committee have fashioned a well-meaning effort to modernize the Medicare drug benefit. Among its key features, the bill would help protect seniors from high out-of-pocket costs by limiting beneficiary cost sharing to $3,100 annually. It then seeks to offset some of these new subsidies by capping the increases that drug makers can take on the list price of their medicines.
In this way, the bill reflects a wider policy struggle underway in our debate over drug pricing. On the one hand, drug makers want to broaden coverage for medicines in programs like Medicare and Obamacare as a way to better insulate consumers from drug costs. On the other hand, policy makers don’t want to expand government funding for drugs without imposing more control over how these products are priced.
Click to read more
Relevant and recent posts
Leana Wen: How long does covid booster protection last?
More evidence highlighting the benefit, and limitations, of covid-19 vaccines. After the Centers for Disease Control and Prevention shifted its coronavirus vaccine guidance from a…
Thought Leader: Leana Wen
Dr. Sanjay Gupta: How Wearable Tech Transforms Health
We’ve come a long way in integrating technology into our daily lives, but could wearable tech actually help you live longer? From detecting heartbeat irregularities to flagging signs of…
Thought Leader: Sanjay Gupta
More with this speaker
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb
Scott Gottlieb: China’s edge over U.S. biotech
Thought Leader: Scott Gottlieb